(Q34071671)

English

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Svend Strandgaard

4

object named as

Svend Strandgaard

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Anne-Lise Kamper

0 references

author name string

Lene Boesby

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Thomas Elung-Jensen

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Tobias Wirenfeldt Klausen

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Anne-Lise Kamper

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

4 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

e26904

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

copyright license

Creative Commons Attribution 4.0 International

4 November 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Aldosterone and glomerular podocyte injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Rapid non-genomic effects of aldosterone on the renal vasculature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Aldosterone target organ protection by eplerenone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Aldosterone in progressive renal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3208556

5 July 2018

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Beneficial impact of spironolactone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0026904

21 January 2018

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22073219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22073219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22073219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker

1 reference

https://pubmed.ncbi.nlm.nih.gov/22073219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://pubmed.ncbi.nlm.nih.gov/22073219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22073219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22073219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0026904

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2011PLoSO...626904B

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34071671&oldid=1868642859"